ALLMedicine™ Graft Versus Host Disease Center
Research & Reviews 822 results
https://doi.org/10.1007/s00277-022-04863-2 10.1056/NEJMoa1301689 10.1024/0040-5930/a001126 10.1007/s12185-018-2412-8 10.1097/moh.0000000000000408 10.1111/j.1365-2141.2004.05282.x 10.1056/nejm199812033392301 10.1016/s0140-6736(97)09214-3 10.1182/blood-2011-07-370247 10.1016/j.leukres.2016.12.001 10.1182/blood-2013-05-503847 10.1038/leu.2014.332 10.1016/j.leukres.2017.01.026 10.1007/s12185-019-02759-y 10.1172/jci.insight.89278 10.1182/blood.V84.3.964.964 10.1158/1078-0432.Ccr-13-3205 10.1136/jcp.53.1.49 10.1016/s0065-2776(04)86006-1 10.1182/blood.V74.5.1690.1690 10.1097/hs9.0000000000000159 10.1182/blood.V78.9.2182.2182 10.1182/blood.V84.7.2158.2158 10.3109/10428199809059227 10.1007/s12253-017-0266-7 10.1002/hon.2806 10.1182/blood-2015-07-604546 10.1200/jco.2009.23.2652 10.1200/jco.2008.17.0472 10.1182/blood-2011-02-337725 10.1182/blood-2005-10-4073 10.1111/j.1600-0609.1991.tb01560.x 10.1038/leu.2016.252 10.1200/jco.2003.12.125 10.1182/blood-2016-03-674127 10.1182/blood-2009-07-235358 10.1182/blood-2016-08-733196 10.1182/blood-2008-02-140095 10.1038/leu.2015.98 10.1182/blood-2015-04-639831 10.1182/blood-2015-02-627786
Annals of Hematology; Zeng Q, Xiang B et. al.
May 16th, 2022 - High-dose chemotherapy followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) is generally the optimal option for patients with acute myeloid leukemia (AML). However, for favorable- and intermediate-risk patients, the regimen r...
https://doi.org/10.1002/ajh.26594
American Journal of Hematology; Gottlieb DJ, Sutrave G et. al.
May 14th, 2022 - We designed a trial to simultaneously address the problems of graft versus host disease (GVHD), infection and recurrence of malignancy after allogeneic stem cell transplantation. CD34+ stem cell isolation was used to minimise the development of ac...
https://clinicaltrials.gov/ct2/show/NCT02356159
May 13th, 2022 - Background: Graft versus host disease (GVHD) and impaired immune reconstitution are major transplant complications and barriers to improving outcomes after allogeneic hematopoietic stem cell transplantation (alloHSCT) for hematologic malignancies....
https://clinicaltrials.gov/ct2/show/NCT04160390
May 12th, 2022 - PRIMARY OBJECTIVES: I. To determine whether endogenous metabolomics compounds obtained before cyclophosphamide administration can predict the ratio of 4hydroxycyclophosphamide to cyclophosphamide area under the curve (4HCY/CY AUC). II. To validate...
https://clinicaltrials.gov/ct2/show/NCT03096782
May 12th, 2022 - PRIMARY OBJECTIVES: I. To evaluate the safety and feasibility of transplantation of cord blood which is expanded in mesenchymal precursor cell (MPC) co-cultures then fucosylated with fucosyltransferase (FT)-VI and guanosine diphosphate (GDP) fucos...
Guidelines 3 results
https://doi.org/10.1016/S2352-3026(19)30256-X
The Lancet. Haematology; Penack O, Marchetti M et. al.
Feb 1st, 2020 - Graft-versus-host disease (GVHD) is a major factor contributing to mortality and morbidity after allogeneic stem-cell transplantation. Because of the small number of results from well designed, large-scale, clinical studies there is considerable v...
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4291097
Journal of the European Academy of Dermatology and Venere... Knobler R, Berlin G et. al.
Dec 21st, 2013 - After the first investigational study on the use of extracorporeal photopheresis for the treatment of cutaneous T-cell lymphoma was published in 1983 with its subsequent recognition by the FDA for its refractory forms, the technology has shown sig...
https://doi.org/10.1111/j.1445-5994.2008.01723.x
Internal Medicine Journal; Slavin MA, Heath CH et. al.
Jul 1st, 2008 - Antifungal prophylaxis can be recommended in patients undergoing induction chemotherapy for acute myeloid leukemia and treatment for grade 2 or greater or chronic extensive graft versus host disease. The evidence for prophylaxis is less clear in o...
Drugs 1 results see all →
Clinicaltrials.gov 196 results
https://clinicaltrials.gov/ct2/show/NCT02356159
May 13th, 2022 - Background: Graft versus host disease (GVHD) and impaired immune reconstitution are major transplant complications and barriers to improving outcomes after allogeneic hematopoietic stem cell transplantation (alloHSCT) for hematologic malignancies....
https://clinicaltrials.gov/ct2/show/NCT03096782
May 12th, 2022 - PRIMARY OBJECTIVES: I. To evaluate the safety and feasibility of transplantation of cord blood which is expanded in mesenchymal precursor cell (MPC) co-cultures then fucosylated with fucosyltransferase (FT)-VI and guanosine diphosphate (GDP) fucos...
https://clinicaltrials.gov/ct2/show/NCT04160390
May 12th, 2022 - PRIMARY OBJECTIVES: I. To determine whether endogenous metabolomics compounds obtained before cyclophosphamide administration can predict the ratio of 4hydroxycyclophosphamide to cyclophosphamide area under the curve (4HCY/CY AUC). II. To validate...
https://clinicaltrials.gov/ct2/show/NCT03591302
May 10th, 2022 - This is a single-center, open-label study in adult renal transplant patients.Twenty five patients with functioning HLA matched living donor kidney transplants will receive TLI, rATG and an infusion of cluster of differentiation (CD)34+ (Stem/Proge...
https://clinicaltrials.gov/ct2/show/NCT05367583
May 10th, 2022 - Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid disorders due to qualitative defects of the hematopoietic stem cell, resulting in uneffective hematopoiesis, dysplasia of one or more lineages, and subsequently, various cytopeni...
News 42 results
https://www.onclive.com/view/itolizumab-under-further-investigation-in-equator-trial-as-frontline-agvhd-treatment
Apr 1st, 2022 - The addition of itolizumab to standard-of-care (SOC) corticosteroids vs placebo will be evaluated in patients with acute graft-versus-host disease (aGVHD), as part of the phase 3 EQUATOR trial (NCT05263999), according to John Koreth, MBBS, DPhil, ...
https://www.onclive.com/view/fda-approval-sought-for-ibrutinib-in-pediatric-chronic-graft-versus-host-disease
Feb 28th, 2022 - A supplemental new drug application (sNDA) has been submitted to the FDA seeking the approval of ibrutinib (Imbruvica) for the treatment of pediatric and adolescent patients aged 1 year and older with chronic graft-vs-host disease (cGVHD) followin...
https://www.onclive.com/view/an-overview-of-treatment-options-for-chronic-gvhd
Nov 15th, 2021 - Transcript: Corey Cutler, MD, MPH, FRCPC: Acute and chronic graft versus host disease [GVHD] are managed very similarly, at least in the upfront setting, where corticosteroids really are the mainstay of treatment. In the chronic GVHD setting, we ...
https://www.onclive.com/view/prophylactic-strategies-in-graft-vs-host-disease-management
Nov 15th, 2021 - Transcript: Corey Cutler, MD, MPH, FRCPC: GVHD [graft versus host disease] prophylaxis is universal. The only time that we don’t do prophylaxis is when you have a transplant from identical twins, or when you are using the patient as their own don...
https://www.mdedge.com/hematology-oncology/article/247811/cml/allo-hct-outcomes-cml-patients-previously-treated-2g-tkis
Oct 24th, 2021 - Key clinical point: Treatment with the second-generation (2G) tyrosine kinase inhibitors (TKI) before allogeneic hematopoietic cell transplantation (allo-HCT) is feasible without any detrimental posttransplant outcomes or additional transplant-rel.
